Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Kidney cancer pathology in the new context of targeted therapy.

Pathobiology : journal of immunopathology, molecular and cellular biology - 1 Jan 2011

Allory Yves, Culine Stéphane, de la Taille Alexandre

Abstract excerpt

The outcome in metastatic renal cancer remains poor with an overall survival at 5 years of less than 10%. However, molecular pathology in kidney cancer has developed extensively in the few last years, providing a basis for new systemic therapies including antiangiogenic drugs and mTOR inhibitors. Use of these targeted therapies in metastatic disease has improved the prognosis but still in a too-limited range,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, myc

Share to Hypoxia-Inducible Factor 1

Share to Kidney Neoplasms

Share to Proto-Oncogene Proteins c-met

Share to TOR Serine-Threonine Kinases

Share to Von Hippel-Lindau Tumor Suppressor Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 21677472
DOI: 10.1159/000315543
PMCID: PMC3361895

Genes

MET
MYC
VHL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Kidney cancer pathology in the new context of targeted therapy.PMID 21677472Read ↗

Oncotargets in Different Renal Cancer SubtypesSemantic proximity Read ↗

Renal Cell Carcinoma in von Hippel–Lindau Disease—From Tumor Genetics to Novel Therapeutic StrategiesSemantic proximity Read ↗

Current updates and future perspectives on the management of renal cell carcinoma.Semantic proximity Read ↗

Anti-Angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-CarcinomaSemantic proximity Read ↗

Targeting miRNAs in renal cell carcinoma: emerging therapeutic strategiesSemantic proximity Read ↗

Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective.Semantic proximity Read ↗

Kidney cancer: identification of novel targets for therapy.Semantic proximity Read ↗

From bench to bedside: current and future applications of molecular profiling in renal cell carcinomaSemantic proximity Read ↗

Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted TherapiesSemantic proximity Read ↗

Signaling pathways in renal cell carcinoma.Semantic proximity Read ↗

Molecular basis for the treatment of renal cell carcinoma.Semantic proximity Read ↗

The New WHO Category of “Molecularly Defined Renal Carcinomas”: Clinical and Diagnostic Features and Management ImplicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.